A reduction in flow-rate across the aortic valve and a murmur that is less audible are consequences of left ventricular systolic dysfunction.

Aortic Stenosis: Symptoms, Causes, and Management

Aortic stenosis is a condition characterized by the narrowing of the aortic valve, which can lead to various symptoms. These symptoms include chest pain, dyspnea, syncope, and a characteristic ejection systolic murmur that radiates to the carotids. Severe aortic stenosis can also cause a narrow pulse pressure, slow rising pulse, delayed ESM, soft/absent S2, S4, thrill, and left ventricular hypertrophy or failure. The most common causes of aortic stenosis are degenerative calcification in older patients and bicuspid aortic valve in younger patients.

If a patient is asymptomatic, observation is usually recommended. However, if the patient is symptomatic or has a valvular gradient greater than 40 mmHg with features such as left ventricular systolic dysfunction, valve replacement is necessary. Surgical AVR is the preferred treatment for young, low/medium operative risk patients, while TAVR is used for those with a high operative risk. Balloon valvuloplasty may be used in children without aortic valve calcification and in adults with critical aortic stenosis who are not fit for valve replacement.

In summary, aortic stenosis is a condition that can cause various symptoms and requires prompt management to prevent complications. The causes of aortic stenosis vary, and treatment options depend on the patient’s age, operative risk, and overall health.

BTS/SIGN Guidelines on Asthma Diagnosis and Management

Guidelines from BTS/SIGN provide recommendations on how to diagnose and manage asthma. Symptoms such as wheezing, breathlessness, chest tightness, or cough, especially if they worsen at night or in the early morning, after exercise, allergy exposure, or cold air, are indicative of asthma. Other factors that support the diagnosis include a family history of atopy or asthma, personal history of atopy, widespread wheezing, low FEV1 or PEFR. However, symptoms such as dizziness, light-headedness, voice disturbance, and chronic cough without wheezing do not suggest asthma. Additionally, there is no evidence that symptoms corresponding to a cold indicate an underlying diagnosis of asthma. These guidelines aim to help healthcare professionals accurately diagnose and manage asthma in patients.

Importance of CT Scan in Evaluating Ureteric Obstruction

A CT scan is necessary to rule out ureteric obstruction, such as a stone or abscess formation, even in cases where there is a significant elevation in creatinine. Although contrast nephropathy is a risk, the likelihood is low with a creatinine level of 125 µmol/L. It is important to note that iodinated contrast is the nephrotoxic component of a CT scan, and a non-contrast CT is both effective and poses minimal risk to the patient.

A plain radiograph may not detect stones that are not radio-opaque, and a micturating cystourethrogram is typically used to identify anatomical or functional abnormalities affecting the lower renal tract. If a CT scan is not feasible in the acute situation, an ultrasound may be a reasonable alternative. Overall, a CT scan is crucial in evaluating ureteric obstruction and should be considered even in cases where there is a slight risk of contrast nephropathy.

After experiencing their first seizure, individuals must wait for a period of 6 months without any further seizures before they can apply to the DVLA to have their license reinstated. However, if they have been diagnosed with epilepsy, they must wait for a minimum of 12 months without any seizures before reapplying to the DVLA for their license to be reissued. It is crucial to understand that it is the patient’s responsibility to inform the DVLA and they should not drive until they have received permission from the DVLA. It is important to note that the medical team is not responsible for informing the DVLA. It is essential to keep in mind that the requirements may differ if the individual intends to drive a public or heavy goods vehicle.

The DVLA has guidelines for drivers with neurological disorders. Those with epilepsy/seizures must not drive and must inform the DVLA. The length of time off driving varies depending on the type and frequency of seizures. Those with syncope may need time off driving depending on the cause and number of episodes. Those with other conditions such as stroke, craniotomy, pituitary tumor, narcolepsy/cataplexy, and chronic neurological disorders should inform the DVLA and may need time off driving.

Widespread convulsions without loss of consciousness may indicate a psychogenic non-epileptic seizure (pseudoseizure), especially in a patient with psychiatric comorbidities. A focal aware seizure would not involve whole-body convulsions, while an alcohol withdrawal seizure would involve loss of consciousness. A panic attack may involve involuntary movement, but widespread convulsions would be unusual.

Understanding Psychogenic Non-Epileptic Seizures

Psychogenic non-epileptic seizures, also known as pseudoseizures, are a type of seizure that is not caused by abnormal electrical activity in the brain. Instead, they are believed to be caused by psychological factors such as stress, trauma, or anxiety. These seizures can be difficult to diagnose as they often mimic true epileptic seizures, but there are certain factors that can help differentiate between the two.

Factors that may indicate pseudoseizures include pelvic thrusting, a family history of epilepsy, a higher incidence in females, crying after the seizure, and the seizures not occurring when the individual is alone. On the other hand, factors that may indicate true epileptic seizures include tongue biting and a raised serum prolactin level.

Video telemetry is a useful tool for differentiating between the two types of seizures. It involves monitoring the individual’s brain activity and behavior during a seizure, which can help determine whether it is caused by abnormal electrical activity in the brain or psychological factors.

It is important to accurately diagnose and treat psychogenic non-epileptic seizures as they can have a significant impact on an individual’s quality of life. Treatment may involve therapy to address underlying psychological factors, as well as medication to manage any associated symptoms such as anxiety or depression.

Prompt drainage alongside antibiotic therapy is necessary for the management of an empyema. Therefore, the correct course of action is to insert a chest drain and commence antibiotic therapy. The diagnosis of empyema can be confirmed using Light’s criteria, which indicates an exudative effusion with a pleural fluid protein to serum protein ratio greater than 0.5 and/or a pleural fluid LDH to serum LDH ratio greater than 0.6. A pleural fluid pH <7.3 and a very low pleural glucose concentration (<1.6 mmol/L) are also indicative of empyema. The normal cell cytology makes malignancy unlikely. The patient's platelet and PT levels are appropriate for chest drain insertion, so there is no need to refer for investigation under the oncology team or to gastroenterology to investigate for liver cirrhosis. Starting IV antibiotics alone is insufficient for managing an empyema, as prompt drainage is necessary to give antibiotics the best chance of success. A chest drain is a tube that is inserted into the pleural cavity to allow air or liquid to move out of the cavity. It is used in cases of pleural effusion, pneumothorax, empyema, haemothorax, haemopneumothorax, chylothorax, and some cases of penetrating chest wall injury in ventilated patients. However, there are relative contraindications to chest drain insertion, such as an INR greater than 1.3, a platelet count less than 75, pulmonary bullae, and pleural adhesions. The patient should be positioned in a supine position or at a 45º angle, and the area should be anaesthetised using local anaesthetic injection. The drainage tube is then inserted using a Seldinger technique and secured with either a straight stitch or an adhesive dressing. Complications that may occur include failure of insertion, bleeding, infection, penetration of the lung, and re-expansion pulmonary oedema. The chest drain should be removed when there has been no output for > 24 hours and imaging shows resolution of the fluid collection or pneumothorax. Drains inserted in cases of penetrating chest injury should be reviewed by the specialist to confirm an appropriate time for removal.

The typical duration of treatment for unprovoked pulmonary embolisms is 6 months, with first-line treatment now being direct oral anticoagulants. Patients are usually reviewed after 3 months, and if no cause was found, treatment is continued for a further 3 months. 3 months would be appropriate for provoked embolisms, but as there was no clear cause in this case, 6 months is more appropriate. 4 months is not a standard duration of treatment, and 12 months is not usual either, although the doctor may decide to extend treatment after review. In some cases, lifelong anticoagulation may be recommended if an underlying prothrombotic condition is found, but for this patient, 6 months is appropriate.

Management of Pulmonary Embolism: NICE Guidelines

Pulmonary embolism (PE) is a serious condition that requires prompt management. The National Institute for Health and Care Excellence (NICE) updated their guidelines on the management of venous thromboembolism (VTE) in 2020, with some key changes. One of the significant changes is the recommendation to use direct oral anticoagulants (DOACs) as the first-line treatment for most people with VTE, including those with active cancer. Another change is the increasing use of outpatient treatment for low-risk PE patients, determined by a validated risk stratification tool.

Anticoagulant therapy is the cornerstone of VTE management, and the guidelines recommend using apixaban or rivaroxaban as the first-line treatment following the diagnosis of a PE. If neither of these is suitable, LMWH followed by dabigatran or edoxaban or LMWH followed by a vitamin K antagonist (VKA) can be used. For patients with active cancer, DOACs are now recommended instead of LMWH. The length of anticoagulation is determined by whether the VTE was provoked or unprovoked, with treatment typically stopped after 3-6 months for provoked VTE and continued for up to 6 months for unprovoked VTE.

In cases of haemodynamic instability, thrombolysis is recommended as the first-line treatment for massive PE with circulatory failure. Patients who have repeat pulmonary embolisms, despite adequate anticoagulation, may be considered for inferior vena cava (IVC) filters. However, the evidence base for IVC filter use is weak.

Overall, the updated NICE guidelines provide clear recommendations for the management of PE, including the use of DOACs as first-line treatment and outpatient management for low-risk patients. The guidelines also emphasize the importance of individualized treatment based on risk stratification and balancing the risks of VTE recurrence and bleeding.

Pregnant women should avoid taking ACE inhibitors like ramipril as they can lead to fetal abnormalities and renal failure. These medications are believed to hinder the production of fetal urine, resulting in oligohydramnios, and increase the likelihood of cranial and cardiac defects. However, other drugs do not pose any known risks during pregnancy and can be continued if necessary.

Angiotensin-converting enzyme (ACE) inhibitors are commonly used as the first-line treatment for hypertension and heart failure in younger patients. However, they may not be as effective in treating hypertensive Afro-Caribbean patients. These inhibitors are also used to treat diabetic nephropathy and for secondary prevention of ischaemic heart disease. The mechanism of action of ACE inhibitors is to inhibit the conversion of angiotensin I to angiotensin II. They are metabolized in the liver through phase 1 metabolism.

ACE inhibitors may cause side effects such as cough, which occurs in around 15% of patients and may occur up to a year after starting treatment. This is thought to be due to increased bradykinin levels. Angioedema may also occur up to a year after starting treatment. Hyperkalaemia and first-dose hypotension are other potential side effects, especially in patients taking diuretics. ACE inhibitors should be avoided during pregnancy and breastfeeding, and caution should be exercised in patients with renovascular disease, aortic stenosis, or hereditary or idiopathic angioedema.

Patients receiving high-dose diuretic therapy (more than 80 mg of furosemide a day) are at an increased risk of hypotension when taking ACE inhibitors. Before initiating treatment, urea and electrolytes should be checked, and after increasing the dose, a rise in creatinine and potassium may be expected. Acceptable changes include an increase in serum creatinine up to 30% from baseline and an increase in potassium up to 5.5 mmol/l. Patients with undiagnosed bilateral renal artery stenosis may experience significant renal impairment. The current NICE guidelines provide a flow chart for the management of hypertension.

Understanding Hepatomegaly and Its Common Causes

Hepatomegaly refers to an enlarged liver, which can be caused by various factors. One of the most common causes is cirrhosis, which can lead to a decrease in liver size in later stages. In this case, the liver is non-tender and firm. Malignancy, such as metastatic spread or primary hepatoma, can also cause hepatomegaly, with a hard and irregular liver edge. Right heart failure can result in a firm, smooth, and tender liver edge, which may be pulsatile.

Other causes of hepatomegaly include viral hepatitis, glandular fever, malaria, abscess (pyogenic or amoebic), hydatid disease, haematological malignancies, haemochromatosis, primary biliary cirrhosis, sarcoidosis, and amyloidosis. It is important to identify the underlying cause of hepatomegaly to determine the appropriate treatment and management plan.

For black TD2M patients diagnosed with hypertension, the first-line antihypertensive should be an angiotensin II receptor blocker, such as Losartan. This is because ARBs are more effective at reducing blood pressure in black African or African-Caribbean patients with diabetes compared to ACE inhibitors. Amlodipine, bendroflumethiazide, and doxazosin are not recommended as first-line antihypertensives for this patient population. Thiazide-like diuretics are only used if blood pressure remains uncontrolled despite treatment with an ACE inhibitor or ARB and a calcium-channel blocker. Alpha-blockers are not used unless blood pressure is not controlled with multiple antihypertensive medications.

NICE updated its guidance on the management of type 2 diabetes mellitus (T2DM) in 2022, reflecting advances in drug therapy and improved evidence regarding newer therapies such as SGLT-2 inhibitors. The first-line drug of choice remains metformin, which should be titrated up slowly to minimize gastrointestinal upset. HbA1c targets should be agreed upon with patients and checked every 3-6 months until stable, with consideration for relaxing targets on a case-by-case basis. Dietary advice includes encouraging high fiber, low glycemic index sources of carbohydrates and controlling intake of foods containing saturated fats and trans fatty acids. Blood pressure targets are the same as for patients without type 2 diabetes, and antiplatelets should not be offered unless a patient has existing cardiovascular disease. Only patients with a 10-year cardiovascular risk > 10% should be offered a statin, with atorvastatin 20 mg as the first-line choice.

Propranolol is the preferred medication for migraine prevention in women of childbearing age, as it is safer than topiramate which is teratogenic. Both medications are equally effective, but propranolol has a better side effects profile. Amitriptyline can also be used for migraine prophylaxis, but it is usually reserved for cases where propranolol and topiramate are ineffective. Paracetamol is only recommended for acute management of migraine, while sumatriptan is only recommended for acute management and should not be taken more than twice a week to avoid medication overuse headaches.

Managing Migraines: Guidelines and Treatment Options

Migraines can be debilitating and affect a significant portion of the population. To manage migraines, it is important to understand the different treatment options available. According to the National Institute for Health and Care Excellence (NICE) guidelines, acute treatment for migraines involves a combination of an oral triptan and an NSAID or paracetamol. For young people aged 12-17 years, a nasal triptan may be preferred. If these measures are not effective, non-oral preparations of metoclopramide or prochlorperazine may be considered, along with a non-oral NSAID or triptan.

Prophylaxis should be given if patients are experiencing two or more attacks per month. NICE recommends topiramate or propranolol, depending on the patient’s preference, comorbidities, and risk of adverse events. Propranolol is preferred in women of childbearing age as topiramate may be teratogenic and reduce the effectiveness of hormonal contraceptives. Acupuncture and riboflavin may also be effective in reducing migraine frequency and intensity for some people. For women with predictable menstrual migraines, frovatriptan or zolmitriptan may be recommended as a type of mini-prophylaxis.

Specialists may consider other treatment options, such as candesartan or monoclonal antibodies directed against the calcitonin gene-related peptide (CGRP) receptor, like erenumab. However, pizotifen is no longer recommended due to common adverse effects like weight gain and drowsiness. It is important to exercise caution with young patients as acute dystonic reactions may develop. By following these guidelines and considering various treatment options, migraines can be effectively managed.

Patients who exhibit signs of shock and bradycardia should be administered 500 micrograms of atropine, which can be repeated up to a maximum of 3mg. In the case of this patient, who has experienced syncope and is unstable, atropine is necessary. Amiodarone is used for tachycardias, while bisoprolol is used for rate control in longstanding tachycardias. DC cardioversion is used for tachycardia, and if atropine is ineffective, transcutaneous pacing may be considered. IV saline would not be beneficial in this case, as the patient’s hypotension is caused by bradycardia rather than hypovolemia.

Management of Bradycardia in Peri-Arrest Rhythms

The 2021 Resuscitation Council (UK) guidelines highlight that the management of bradycardia in peri-arrest rhythms depends on two factors. Firstly, identifying adverse signs that indicate haemodynamic compromise, such as shock, syncope, myocardial ischaemia, or heart failure. Secondly, identifying the potential risk of asystole, which can occur in patients with complete heart block with broad complex QRS, recent asystole, Mobitz type II AV block, or ventricular pause > 3 seconds.

If adverse signs are present, Atropine (500mcg IV) is the first line treatment. If there is an unsatisfactory response, interventions such as atropine (up to a maximum of 3mg), transcutaneous pacing, or isoprenaline/adrenaline infusion titrated to response may be used. Specialist help should be sought for consideration of transvenous pacing if there is no response to the above measures.

Even if there is a satisfactory response to atropine, specialist help is indicated to consider the need for transvenous pacing in patients with risk factors for asystole. By following these guidelines, healthcare professionals can effectively manage bradycardia in peri-arrest rhythms and improve patient outcomes.

When a patient with an acute exacerbation of COPD shows signs of respiratory acidosis (PaCO2>6 kPa, pH <7.35 ≥7.26) that persist despite immediate maximum standard medical treatment, it is recommended to consider the use of non-invasive ventilation (NIV). This is particularly important in cases where the patient is severely ill, as in the case of this patient with an infectious exacerbation of COPD. The British Thoracic Society guidelines suggest that NIV should be considered after maximal medical therapy, which in this case includes nebulisers, steroids, and theophylline. While there are other concerning features of this patient's condition, the PaCO2 and pH levels are the key indicators for the use of NIV. Guidelines for Non-Invasive Ventilation in Acute Respiratory Failure The British Thoracic Society (BTS) and the Royal College of Physicians have published guidelines for the use of non-invasive ventilation (NIV) in acute respiratory failure. NIV can be used in patients with COPD and respiratory acidosis with a pH of 7.25-7.35. However, patients with a pH lower than 7.25 require greater monitoring and a lower threshold for intubation and ventilation. NIV is also recommended for type II respiratory failure due to chest wall deformity, neuromuscular disease, or obstructive sleep apnea, as well as for cardiogenic pulmonary edema unresponsive to continuous positive airway pressure (CPAP) and weaning from tracheal intubation. For patients with COPD, the recommended initial settings for bi-level pressure support include an expiratory positive airway pressure (EPAP) of 4-5 cm H2O, an inspiratory positive airway pressure (IPAP) of 10-15 cm H2O, a back-up rate of 15 breaths/min, and a back-up inspiration-to-expiration ratio of 1:3. These guidelines aim to improve patient outcomes and reduce the need for invasive mechanical ventilation.

WHO Recommendations for Diabetes and Intermediate Hyperglycaemia Diagnosis

The World Health Organization (WHO) has established diagnostic criteria for diabetes and intermediate hyperglycaemia. According to the 2006 recommendations, a fasting plasma glucose level of 7.0 mmol/L (126 mg/dL) or higher, or a 2-hour plasma glucose level of 11.1 mmol/L (200 mg/dL) or higher indicates diabetes. On the other hand, impaired glucose tolerance (IGT) is diagnosed when the fasting plasma glucose level is less than 7.0 mmol/L (126 mg/dL) and the 2-hour plasma glucose level is between 7.8 and 11.1 mmol/L (140 mg/dL and 200 mg/dL). Impaired fasting glucose (IFG) is diagnosed when the fasting plasma glucose level is between 6.1 and 6.9 mmol/L (110 mg/dL to 125 mg/dL) and the 2-hour plasma glucose level is less than 7.8 mmol/L (140 mg/dL), if measured.

It is important to note that if the 2-hour plasma glucose level is not measured, the status of the individual is uncertain as diabetes or IGT cannot be excluded. These recommendations serve as a guide for healthcare professionals in diagnosing and managing diabetes and intermediate hyperglycaemia.

If the HbA1c level in type 2 diabetes mellitus is above 58 mmol/mol, a second drug should be added.

When a patient’s HbA1c result indicates poor glucose control, it may be due to various factors such as tolerance, adherence, or lifestyle issues. In such cases, the next step is to prescribe a second medication, which could be a DPP-4 inhibitor, sulfonylurea, or SGLT-2 inhibitor, based on the patient’s needs and after weighing the risks and benefits of each option.

The standard dose of metformin is 500g daily, which can be increased up to a maximum of 2g daily, divided into separate doses. However, if the patient is already on 2g, the dose cannot be increased further. Thiazolidinediones like pioglitazone are not recommended for patients with heart failure and are rarely used as first or second-line therapies.

Since the patient’s HbA1c levels exceed 58 mmol/mol, an additional intervention is necessary, along with reinforcing lifestyle and dietary advice. Insulin is typically reserved for patients who do not respond to double or triple therapy.

NICE updated its guidance on the management of type 2 diabetes mellitus (T2DM) in 2022, reflecting advances in drug therapy and improved evidence regarding newer therapies such as SGLT-2 inhibitors. The first-line drug of choice remains metformin, which should be titrated up slowly to minimize gastrointestinal upset. HbA1c targets should be agreed upon with patients and checked every 3-6 months until stable, with consideration for relaxing targets on a case-by-case basis. Dietary advice includes encouraging high fiber, low glycemic index sources of carbohydrates and controlling intake of foods containing saturated fats and trans fatty acids. Blood pressure targets are the same as for patients without type 2 diabetes, and antiplatelets should not be offered unless a patient has existing cardiovascular disease. Only patients with a 10-year cardiovascular risk > 10% should be offered a statin, with atorvastatin 20 mg as the first-line choice.

The most probable diagnosis for individuals experiencing pain in the peri-umbilical region is acute appendicitis. Early appendicitis is characterized by this type of pain, and a positive psoas sign is also present. A neutrophil predominant leucocytosis is observed on the full blood count, indicating an infection. Ovarian torsion can cause sharp pain, but it is typically sudden and severe, not gradually worsening over 12 hours. Inguinal hernia pain is more likely to be felt in the groin area, not peri-umbilical, and there is no mention of a mass during the abdominal examination. Suprapubic pain and lower urinary tract symptoms such as dysuria are more likely to be associated with a lower urinary tract infection. In the absence of high fever and/or flank pain, an upper urinary tract infection is unlikely.

Understanding Acute Appendicitis

Acute appendicitis is a common condition that requires surgery and can occur at any age, but is most prevalent in young people aged 10-20 years. The pathogenesis of acute appendicitis involves lymphoid hyperplasia or a faecolith, which leads to the obstruction of the appendiceal lumen. This obstruction causes gut organisms to invade the appendix wall, leading to oedema, ischaemia, and possible perforation.

The most common symptom of acute appendicitis is abdominal pain, which is usually peri-umbilical and radiates to the right iliac fossa due to localised peritoneal inflammation. Other symptoms include mild pyrexia, anorexia, and nausea. Examination may reveal generalised or localised peritonism, rebound and percussion tenderness, guarding, and rigidity.

Diagnosis of acute appendicitis is typically based on raised inflammatory markers, compatible history, and examination findings. Imaging may be used in some cases, such as ultrasound in females where pelvic organ pathology is suspected. The treatment of choice for acute appendicitis is appendicectomy, which can be performed via an open or laparoscopic approach. Patients with perforated appendicitis require copious abdominal lavage, while those without peritonitis who have an appendix mass should receive broad-spectrum antibiotics and consideration given to performing an interval appendicectomy.

In conclusion, acute appendicitis is a common condition that requires prompt diagnosis and treatment. Understanding the pathogenesis, symptoms, and management of acute appendicitis is crucial for healthcare professionals to provide appropriate care for patients.

For a patient with a large artery acute ischaemic stroke, mechanical clot retrieval should be considered along with intravenous thrombolysis. According to recent NICE guidance, thrombectomy should be offered as soon as possible and within 6 hours of symptom onset, along with intravenous thrombolysis (if within 4.5 hours), for patients with an acute ischaemic stroke and confirmed occlusion of the proximal anterior circulation demonstrated by computed tomographic angiography (CTA) or magnetic resonance angiography (MRA). As such, this patient should be offered both thrombolysis and clot retrieval. Anticoagulation with Apixaban is not recommended for atrial fibrillation until two weeks after the onset of an ischaemic stroke. Aspirin 300mg would be a reasonable treatment if the patient presented outside the thrombolysis window and mechanical thrombectomy was not an option. However, in this scenario, the patient is within the thrombolysis window and should be offered both thrombolysis and mechanical thrombectomy due to the timing and location of their stroke.

The Royal College of Physicians (RCP) and NICE have published guidelines on the diagnosis and management of patients following a stroke. The management of acute stroke includes maintaining normal levels of blood glucose, hydration, oxygen saturation, and temperature. Blood pressure should not be lowered in the acute phase unless there are complications. Aspirin should be given as soon as possible if a haemorrhagic stroke has been excluded. Anticoagulants should not be started until brain imaging has excluded haemorrhage. Thrombolysis with alteplase should only be given if administered within 4.5 hours of onset of stroke symptoms and haemorrhage has been definitively excluded. Mechanical thrombectomy is a new treatment option for patients with an acute ischaemic stroke. NICE recommends thrombectomy for people who have acute ischaemic stroke and confirmed occlusion of the proximal anterior circulation demonstrated by computed tomographic angiography or magnetic resonance angiography. Secondary prevention includes the use of clopidogrel and dipyridamole. Carotid artery endarterectomy should only be considered if carotid stenosis is greater than 70% according to ECST criteria or greater than 50% according to NASCET criteria.

Gallstones: Symptoms, Diagnosis, and Treatment

Gallstones are a common condition, with up to 24% of women and 12% of men affected. Local infection and cholecystitis may develop in up to 30% of cases, and 12% of patients undergoing surgery will have stones in the common bile duct. The majority of gallstones are of mixed composition, with pure cholesterol stones accounting for 20% of cases. Symptoms typically include colicky right upper quadrant pain that worsens after fatty meals. Diagnosis involves abdominal ultrasound and liver function tests, with magnetic resonance cholangiography or intraoperative imaging used to confirm the presence of stones in the bile duct. Treatment options include expectant management for asymptomatic gallstones, laparoscopic cholecystectomy for symptomatic gallstones, and early ERCP or surgical exploration for stones in the bile duct. Intraoperative cholangiography or laparoscopic ultrasound may be used to confirm anatomy or exclude CBD stones during surgery. ERCP carries risks such as bleeding, duodenal perforation, cholangitis, and pancreatitis.

Beta-blockers are frequently prescribed for hypertension treatment, but they can lead to cold extremities as a side effect. Thiazide diuretics like bendroflumethiazide commonly cause constipation, diarrhea, dizziness, and dry mouth. Angiotensin receptor blockers such as candesartan and losartan do not typically result in cold peripheries.

Beta-blockers are a class of drugs that are primarily used to manage cardiovascular disorders. They have a wide range of indications, including angina, post-myocardial infarction, heart failure, arrhythmias, hypertension, thyrotoxicosis, migraine prophylaxis, and anxiety. Beta-blockers were previously avoided in heart failure, but recent evidence suggests that certain beta-blockers can improve both symptoms and mortality. They have also replaced digoxin as the rate-control drug of choice in atrial fibrillation. However, their role in reducing stroke and myocardial infarction has diminished in recent years due to a lack of evidence. Examples of beta-blockers include atenolol and propranolol, which was one of the first beta-blockers to be developed and is lipid soluble, allowing it to cross the blood-brain barrier.

Like all drugs, beta-blockers have side-effects, including bronchospasm, cold peripheries, fatigue, sleep disturbances (including nightmares), and erectile dysfunction. They are contraindicated in uncontrolled heart failure, asthma, sick sinus syndrome, and concurrent use with verapamil, which may precipitate severe bradycardia.

Intravenous contrast media can lead to contrast induced nephropathy (CIN) in susceptible individuals, particularly those with chronic kidney disease. The best prophylactic intervention is optimal hydration with 0.9% NaCl or 1.26% sodium bicarbonate. N-acetylcysteine is no longer recommended as a potential intervention. Metformin and ramipril can be continued during a contrast-associated intervention as long as renal function is monitored closely. Discontinuation of metformin is not necessary as studies have not proven a significant causal link between impaired renal function and potential lactic acidosis.

Acute kidney injury (AKI) is a condition where there is a sudden decrease in kidney function, which can be defined by a decrease in glomerular filtration rate (GFR) or a decrease in urine output. AKI can be caused by various factors such as prerenal, renal, or postrenal causes. Medications can also cause AKI, and caution should be taken when prescribing ACE inhibitors to patients with declining renal function. In the event of an AKI, certain medications such as ACE inhibitors, A2RBs, NSAIDs, diuretics, aminoglycosides, metformin, and lithium should be temporarily discontinued. Atorvastatin and bisoprolol are safe to prescribe in patients with kidney disease, while finasteride and tamsulosin can be prescribed for benign prostatic hyperplasia but should be used with caution in patients with poor renal function.

Understanding Acute Kidney Injury: A Basic Overview

Acute kidney injury (AKI) is a condition where the kidneys experience a reduction in function due to an insult. In the past, the kidneys were often neglected in acute medicine, resulting in slow recognition and limited action. However, around 15% of patients admitted to the hospital develop AKI. While most patients recover their renal function, some may have long-term impaired kidney function due to AKI, which can result in acute complications, including death. Identifying patients at increased risk of AKI is crucial in reducing its incidence. Risk factors for AKI include chronic kidney disease, other organ failure/chronic disease, a history of AKI, and the use of drugs with nephrotoxic potential.

AKI has three main causes: prerenal, intrinsic, and postrenal. Prerenal causes are due to a lack of blood flow to the kidneys, while intrinsic causes relate to intrinsic damage to the kidneys themselves. Postrenal causes occur when there is an obstruction to the urine coming from the kidneys. Symptoms of AKI include reduced urine output, fluid overload, arrhythmias, and features of uraemia. Diagnosis of AKI is made through blood tests, urinalysis, and imaging.

The management of AKI is largely supportive, with careful fluid balance and medication review being crucial. Loop diuretics and low-dose dopamine are not recommended, but hyperkalaemia needs prompt treatment to avoid life-threatening arrhythmias. Renal replacement therapy may be necessary in severe cases. Prompt review by a urologist is required for patients with suspected AKI secondary to urinary obstruction, while specialist input from a nephrologist is necessary for cases where the cause is unknown or the AKI is severe.

Fractures in the middle of the humerus bone often result in damage to the radial nerve. Therefore, it is important to test the function of the radial nerve. Among the options given, only extending the wrist can effectively test the radial nerve as it provides innervation to the extensor muscles. If the radial nerve is affected, it can cause wrist drop.
While extending the elbow can also test the radial nerve, it may not provide as much information as wrist extension because the injury may be located proximal to the innervation of the triceps. This means that a more distal injury could be missed. Nonetheless, it is still likely to be performed as part of the testing process.
Reference:
Shao YC, Harwood P, Grotz MR, et al. (2005). Radial nerve palsy associated with fractures of the shaft of the humerus: a systematic review. J Bone Joint Surg Br; 87(12):1647-52.

Anatomy and Function of the Radial Nerve

The radial nerve is a continuation of the posterior cord of the brachial plexus, with root values ranging from C5 to T1. It has both motor and sensory functions, innervating muscles in the arm and forearm, as well as providing sensation to the dorsal aspect of the hand.

The nerve follows a path from the axilla, where it lies posterior to the axillary artery on subscapularis, latissimus dorsi, and teres major, to the arm, where it enters between the brachial artery and the long head of triceps. It spirals around the posterior surface of the humerus in the groove for the radial nerve before piercing the intermuscular septum and descending in front of the lateral epicondyle. At the lateral epicondyle, it divides into a superficial and deep terminal branch, with the deep branch crossing the supinator to become the posterior interosseous nerve.

The radial nerve innervates several muscles, including triceps, anconeus, brachioradialis, and extensor carpi radialis. Damage to the nerve can result in wrist drop and sensory loss to a small area between the dorsal aspect of the 1st and 2nd metacarpals. In the forearm, the nerve innervates the supinator, extensor carpi ulnaris, extensor digitorum, extensor indicis, extensor digiti minimi, extensor pollicis longus and brevis, and abductor pollicis longus. Paralysis of these muscles can result in weakening of supination of prone hand and elbow flexion in mid prone position.

Understanding the anatomy and function of the radial nerve is important in diagnosing and treating injuries or conditions that affect its function.

Generalised lymphadenopathy can be caused by several conditions, including CMV and Infectious mononucleosis (IM), which are mentioned in the question. However, the presence of large swollen tonsils and a palpable mass in the left hypochondriac regions, which suggests splenomegaly, together with the patient’s history, highly suggests IM. Tonsillitis, viral throat infection, and dengue fever do not typically present with generalised lymphadenopathy or splenomegaly.

Understanding Infectious Mononucleosis

Infectious mononucleosis, also known as glandular fever, is a viral infection caused by the Epstein-Barr virus (EBV) in 90% of cases. It is most commonly seen in adolescents and young adults. The classic triad of symptoms includes sore throat, pyrexia, and lymphadenopathy, which are present in around 98% of patients. Other symptoms include malaise, anorexia, headache, palatal petechiae, splenomegaly, hepatitis, lymphocytosis, haemolytic anaemia, and a maculopapular rash. The symptoms typically resolve after 2-4 weeks.

The diagnosis of infectious mononucleosis is confirmed through a heterophile antibody test (Monospot test) in the second week of the illness. Management is supportive and includes rest, drinking plenty of fluids, avoiding alcohol, and taking simple analgesia for any aches or pains. It is recommended to avoid playing contact sports for 4 weeks after having glandular fever to reduce the risk of splenic rupture.

Interestingly, there is a correlation between EBV and socioeconomic groups. Lower socioeconomic groups have high rates of EBV seropositivity, having frequently acquired EBV in early childhood when the primary infection is often subclinical. However, higher socioeconomic groups show a higher incidence of infectious mononucleosis, as acquiring EBV in adolescence or early adulthood results in symptomatic disease.

The management of vitamin B12 deficiency typically involves intramuscular replacement of B12, with a loading regimen followed by injections every 2-3 months. Patients with this deficiency may experience symptoms such as fatigue, poor concentration, and pallor, and blood tests may confirm the presence of anemia, low B12, low folate, and hypersegmented polymorphs on a blood film. In some cases, patients may also experience thrombocytopenia due to the role of B12 as a co-factor in bone marrow cell synthesis. While patients with neurological symptoms or who are pregnant should be urgently referred, this patient does not meet those criteria. Referral to haematology may be necessary if the patient has a suspected blood disorder or malignancy, fails to respond to treatment, or has a persistently high mean cell volume. Referral to gastroenterology may be necessary if the patient has a malabsorption syndrome, gastric cancer, or pernicious anemia with gastrointestinal symptoms. Intramuscular replacement of B12 is preferred over oral replacement, as per NICE guidelines, and should always be administered prior to folate replacement to avoid spinal cord degeneration.

Understanding Pernicious Anaemia

Pernicious anaemia is a condition that results in vitamin B12 deficiency due to an autoimmune disorder affecting the gastric mucosa. The term pernicious means causing harm in a gradual or subtle way, and this is reflected in the often subtle symptoms and delayed diagnosis of the condition. While pernicious anaemia is the most common cause of vitamin B12 deficiency, other causes include atrophic gastritis, gastrectomy, and malnutrition.

The pathophysiology of pernicious anaemia involves antibodies to intrinsic factor and/or gastric parietal cells. These antibodies can bind to intrinsic factor, blocking the vitamin B12 binding site, or reduce acid production and cause atrophic gastritis. This leads to reduced intrinsic factor production and reduced vitamin B12 absorption, which can result in megaloblastic anaemia and neuropathy.

Risk factors for pernicious anaemia include being female, middle to old age, and having other autoimmune disorders such as thyroid disease, type 1 diabetes mellitus, Addison’s, rheumatoid arthritis, and vitiligo. It is also more common in individuals with blood group A.

Symptoms of pernicious anaemia include anaemia features such as lethargy, pallor, and dyspnoea, as well as neurological features such as peripheral neuropathy and subacute combined degeneration of the spinal cord. Neuropsychiatric features such as memory loss, poor concentration, confusion, depression, and irritability may also be present, along with mild jaundice and glossitis.

Diagnosis of pernicious anaemia involves a full blood count, vitamin B12 and folate levels, and testing for antibodies such as anti intrinsic factor antibodies and anti gastric parietal cell antibodies. Treatment involves vitamin B12 replacement, usually given intramuscularly, and folic acid supplementation may also be required. Complications of pernicious anaemia include an increased risk of gastric cancer.

Lactulose and rifaximin are the recommended medications for secondary prophylaxis of hepatic encephalopathy. This condition is characterized by confusion, altered consciousness, asterixis, and triphasic slow waves on EEG, and is caused by excess absorption of ammonia and glutamine from bacterial breakdown of proteins in the gut. Lactulose promotes the excretion of ammonia and increases its metabolism by gut bacteria, while rifaximin modulates the gut flora to decrease ammonia production. Spironolactone and furosemide are not used for hepatic encephalopathy, but rather for managing ascites and edema in patients with hypoalbuminemia due to cirrhosis. Propranolol is also not used for prophylaxis against hepatic encephalopathy, but rather to lower portal pressure and prevent variceal bleeding.

Understanding Hepatic Encephalopathy

Hepatic encephalopathy is a condition that can occur in individuals with liver disease, regardless of the cause. The exact cause of this condition is not fully understood, but it is believed to be related to the absorption of excess ammonia and glutamine from the breakdown of proteins by bacteria in the gut. While hepatic encephalopathy is commonly associated with acute liver failure, it can also be seen in chronic liver disease. In fact, many patients with liver cirrhosis may experience mild cognitive impairment before the more recognizable symptoms of hepatic encephalopathy appear. It is also worth noting that transjugular intrahepatic portosystemic shunting (TIPSS) can trigger encephalopathy.

The symptoms of hepatic encephalopathy can range from irritability and confusion to incoherence and coma. The condition can be graded based on the severity of the symptoms, with Grade I being the mildest and Grade IV being the most severe. There are several factors that can precipitate hepatic encephalopathy, including infection, gastrointestinal bleeding, constipation, and certain medications.

The management of hepatic encephalopathy involves treating any underlying causes and using medications to alleviate symptoms. Lactulose is often the first-line treatment, as it promotes the excretion of ammonia and increases its metabolism by gut bacteria. Antibiotics such as rifaximin can also be used to modulate the gut flora and reduce ammonia production. In some cases, embolization of portosystemic shunts or liver transplantation may be necessary.

Overall, hepatic encephalopathy is a complex condition that requires careful management and monitoring. By understanding the causes, symptoms, and treatment options, healthcare providers can provide the best possible care for patients with this condition.

When hypothermia leads to cardiac arrest, defibrillation is not as effective and should be limited to three shocks before the patient is warmed up to 30 degrees Celsius. Pacing is also ineffective until the patient reaches normal body temperature. Medications should be held off until the patient reaches 30 degrees Celsius, and then administered at double the usual intervals until the patient achieves normal body temperature or experiences the return of spontaneous circulation (ROSC).

Hypothermia is a condition where the core body temperature drops below normal levels, often caused by exposure to cold environments. It is most common in the winter and the elderly are particularly susceptible. Signs include shivering, cold and pale skin, slurred speech, and confusion. Treatment involves removing the patient from the cold environment, warming the body with blankets, securing the airway, and monitoring breathing. Rapid re-warming should be avoided as it can lead to peripheral vasodilation and shock. Certain actions, such as putting the person in a hot bath or giving them alcohol, should be avoided.

The most common organism associated with bronchiectasis is Haemophilus influenzae, making it the correct answer for an acute exacerbation of this condition. While Klebsiella pneumonia is also a possibility, it is less frequently seen and typically associated with pneumonia in patients with alcohol dependence. Pseudomonas aeruginosa is an incorrect answer, as it is more commonly found in patients with cystic fibrosis than bronchiectasis. Staphylococcus aureus is also less commonly isolated in bronchiectasis, and is more commonly associated with other infective conditions such as infective endocarditis and skin infections, as well as being a secondary bacterial cause of pneumonia following influenzae.

Managing Bronchiectasis

Bronchiectasis is a condition where the airways become permanently dilated due to chronic inflammation or infection. Before starting treatment, it is important to identify any underlying causes that can be treated, such as immune deficiency. The management of bronchiectasis includes physical training, such as inspiratory muscle training, which has been shown to be effective for patients without cystic fibrosis. Postural drainage, antibiotics for exacerbations, and long-term rotating antibiotics for severe cases are also recommended. Bronchodilators may be used in selected cases, and immunizations are important to prevent infections. Surgery may be considered for localized disease. The most common organisms isolated from patients with bronchiectasis include Haemophilus influenzae, Pseudomonas aeruginosa, Klebsiella spp., and Streptococcus pneumoniae.

Spacing:

Bronchiectasis is a condition where the airways become permanently dilated due to chronic inflammation or infection. Before starting treatment, it is important to identify any underlying causes that can be treated, such as immune deficiency.

The management of bronchiectasis includes physical training, such as inspiratory muscle training, which has been shown to be effective for patients without cystic fibrosis. Postural drainage, antibiotics for exacerbations, and long-term rotating antibiotics for severe cases are also recommended. Bronchodilators may be used in selected cases, and immunizations are important to prevent infections. Surgery may be considered for localized disease.

The most common organisms isolated from patients with bronchiectasis include Haemophilus influenzae, Pseudomonas aeruginosa, Klebsiella spp., and Streptococcus pneumoniae.

The middle cerebral artery is associated with contralateral hemiparesis and sensory loss, with the upper extremity being more affected than the lower. It also causes contralateral homonymous hemianopia and aphasia.

When a stroke occurs, the location of the lesion in the brain can determine the specific effects on the body. Depending on which artery is affected, different symptoms may arise. For example, a stroke in the anterior cerebral artery can lead to contralateral hemiparesis and sensory loss, with the lower extremity being more affected than the upper. On the other hand, a stroke in the middle cerebral artery can cause contralateral hemiparesis and sensory loss, with the upper extremity being more affected than the lower, as well as contralateral homonymous hemianopia and aphasia.

If the stroke occurs in the posterior cerebral artery, the individual may experience contralateral homonymous hemianopia with macular sparing and visual agnosia. In the case of Weber’s syndrome, which involves branches of the posterior cerebral artery that supply the midbrain, the person may have an ipsilateral CN III palsy and contralateral weakness of the upper and lower extremities.

Other types of strokes include those affecting the posterior inferior cerebellar artery, which can lead to ipsilateral facial pain and temperature loss and contralateral limb/torso pain and temperature loss, as well as ataxia and nystagmus. A stroke in the anterior inferior cerebellar artery can cause similar symptoms to Wallenberg’s syndrome, but with the addition of ipsilateral facial paralysis and deafness.

Finally, lacunar strokes are small, localized strokes that often occur in individuals with hypertension. They typically present with isolated hemiparesis, hemisensory loss, or hemiparesis with limb ataxia, and commonly affect the basal ganglia, thalamus, and internal capsule.

Adults with polycystic kidney disease are at an increased risk of experiencing subarachnoid haemorrhage due to ruptured berry aneurysms. This is the most significant associated condition, as ADPKD is known to be linked with cerebral berry aneurysms that can rupture and cause subarachnoid haemorrhage. Liver cysts are the most common complication of ADPKD, while colonic diverticula and bowel obstruction are less frequent. Although ADPKD can cause splenic cysts and splenomegaly, this is also less common than the risk of subarachnoid haemorrhage due to cerebral berry aneurysms.

Autosomal dominant polycystic kidney disease (ADPKD) is a prevalent genetic condition that affects approximately 1 in 1,000 Caucasians. The disease is caused by mutations in two genes, PKD1 and PKD2, which produce polycystin-1 and polycystin-2, respectively. ADPKD type 1 accounts for 85% of cases, while ADPKD type 2 accounts for the remaining 15%. Individuals with ADPKD develop multiple fluid-filled cysts in their kidneys, which can lead to renal failure.

To diagnose ADPKD in individuals with a positive family history, an abdominal ultrasound is typically performed. The diagnostic criteria for ultrasound include the presence of two cysts, either unilateral or bilateral, in individuals under 30 years of age, two cysts in both kidneys for those aged 30-59 years, and four cysts in both kidneys for those over 60 years of age.

Management of ADPKD may involve the use of tolvaptan, a vasopressin receptor 2 antagonist, for select patients. Tolvaptan has been recommended by NICE as an option for treating ADPKD in adults with chronic kidney disease stage 2 or 3 at the start of treatment, evidence of rapidly progressing disease, and if the company provides it with the agreed discount in the patient access scheme. The goal of treatment is to slow the progression of cyst development and renal insufficiency. An enlarged kidney with extensive cysts is a common finding in individuals with ADPKD.

In cases of acute kidney injury (AKI), it is important to identify drugs that may worsen renal function and those that can result in toxicity. AKI is defined as a 50% or greater rise in serum creatinine within the past 7 days or a fall in urine output to less than 0.5 ml/kg/hour for more than 6 hours.

For patients on aspirin for secondary prevention of acute coronary syndrome, the cardioprotective dose of 75 mg per day should be continued as there is strong evidence supporting its use. Aspirin is a COX-inhibitor that inhibits thromboxane synthesis via the COX-1 pathway, exhibiting antithrombotic effects.

Drugs that should be stopped in AKI as they may worsen renal function include diuretics, aminoglycosides, ACE inhibitors/ARBs, and NSAIDs that are not at cardioprotective doses. On the other hand, drugs that do not worsen renal function but can result in toxicity include metformin, lithium, and digoxin. A helpful mnemonic to remember the drugs to stop in AKI is DAMN AKI: Diuretics, Aminoglycosides and ACE inhibitors, Metformin, and NSAIDs.

Understanding Acute Kidney Injury: A Basic Overview

Acute kidney injury (AKI) is a condition where the kidneys experience a reduction in function due to an insult. In the past, the kidneys were often neglected in acute medicine, resulting in slow recognition and limited action. However, around 15% of patients admitted to the hospital develop AKI. While most patients recover their renal function, some may have long-term impaired kidney function due to AKI, which can result in acute complications, including death. Identifying patients at increased risk of AKI is crucial in reducing its incidence. Risk factors for AKI include chronic kidney disease, other organ failure/chronic disease, a history of AKI, and the use of drugs with nephrotoxic potential.

AKI has three main causes: prerenal, intrinsic, and postrenal. Prerenal causes are due to a lack of blood flow to the kidneys, while intrinsic causes relate to intrinsic damage to the kidneys themselves. Postrenal causes occur when there is an obstruction to the urine coming from the kidneys. Symptoms of AKI include reduced urine output, fluid overload, arrhythmias, and features of uraemia. Diagnosis of AKI is made through blood tests, urinalysis, and imaging.

The management of AKI is largely supportive, with careful fluid balance and medication review being crucial. Loop diuretics and low-dose dopamine are not recommended, but hyperkalaemia needs prompt treatment to avoid life-threatening arrhythmias. Renal replacement therapy may be necessary in severe cases. Prompt review by a urologist is required for patients with suspected AKI secondary to urinary obstruction, while specialist input from a nephrologist is necessary for cases where the cause is unknown or the AKI is severe.